A lawyer clarifies the nature of ergot, but it remains a tough nut for pharmacists to crack
Crossref DOI link: https://doi.org/10.1007/978-3-662-69811-2_4
Published Online: 2025-04-05
Published Print: 2025
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Petersen, Frank
Funding for this research was provided by:
Syngenta International
Novartis
Emilia-Guggenheim-Schnurr-Stiftung
Text and Data Mining valid from 2025-01-01
Version of Record valid from 2025-01-01
Chapter History
First Online: 5 April 2025